Before becoming LegalReader's Editor-in-Chief, Jay W. Belle Isle worked as a freelance copywriter with clients on four continents. Jay has a degree in Business Administration from Cleary University and a Juris Doctor from Thomas M. Cooley Law School. Jay has also worked as a contracts administrator for a DOD contractor specializing in vehicle armor.
In a press release issued yesterday the FDA adds new warnings about Actos and bladder cancer risk. The diabetes drug pioglitazone, sold as Actos, Actoplus Met, Actoplus Met XR, Duetact and Oseni could increase patients’ risk of developing bladder cancer, prompting the Agency to uphold current label warnings in addition to adding new ones.
Several studies have recently confirmed that Zika virus damage to infants may not show right away. Researchers have discovered that, despite the appearance of normalcy at birth, infants who were exposed to Zika in the womb may present microcephaly and other forms of brain damage as well as vision and hearing problems.
Today’s post is a video post by Dr. Julio Novoa, an advocate for women injured by Essure. The video is published with his permission and runs about 14 minutes. It is very much worth watching. The big takeaway is this: no more plausible deniability for doctors implanting Essure.
Recently, I received a notice from Lou Lombardo, auto safety advocate and creator of Care for Crash Victims, about another well-known automotive safety advocate. I’m pleased to announce that Senator Ed Markey (D-MA) was recognizing Clarence Ditlow’s contributions to Americans’ automotive safety.
Recently, we at LegalReader were honored by Feedspot, a site described as “a Modern RSS Reader. If you’re trying to keep up with news and content on multiple web sites, you’re faced with the never ending task of visiting those sites to check for new content. Feedspot allows you to put all of your reading in one location.” Mr. Anuj Agarwal, Feedspot’s founder, contacted us to let us know that LegalReader was selected as one of the top 100 legal blogs on the web!
This week’s Feel Good Friday is a bit different than most. Usually, I highlight a lawyer or a law firm that does good works in the general communities in which they live and work. This week, I’m highlighting an organization that does good work within the legal community (which then benefits the people helped by the lawyers and firms I usually highlight. So let’s get going, shall we? This Feel Good Friday, I’m highlighting the Pound Civil Justice Institute.
Back in July, I reported that several plaintiffs dealing with the Essure crisis moved to create multidistrict litigation (MDL) and that the motion would be heard by the Judicial Panel on Multidistrict Litigation (JPML) on September 29. Now, I’m back to report that the plaintiffs withdrew the motion for Essure multidistrict litigation. The JPML removed the topic from the hearing schedule.
I recently had the opportunity via e-mail to interview Louis Lombardo on whistleblowing and vehicle emissions. Lou is the publisher of Care For Crash Victims Reports and an advocate for the prevention of vehicle violence. This includes such issues as crashes, emissions damage and the failure of regulatory agencies to properly regulate the auto industry.
The following is a direct re-print (with permission) from the Essure Problems website. Yes, it is a long post. However, it is vital information for any woman considering removal surgery. This blog has reached E-Sisters who were not aware of the website or the Facebook group, therefore, I wanted to publish this piece. I thank Angie Firmalino, one of the website’s administrator’s for permission to do so. If you have Essure and are experiencing problems this Essure removal information is important to have.
On Friday, September 23, Representative Mike Fitzpatrick asked Congress for medical device hearing with the goal of updating safety laws governing such devices. Rep. Fitzpatrick (R-PA) asked the Committee on Energy and Commerce to hold hearings examining the negative effects of “unsafe medical devices on patients and the failings of the U.S. Food and Drug Administration.”